JSI and the Liberia-US Clinical Research Partnership are Impacting Ebola Survivors
The Liberia-US Clinical Research Partnership, PREVAIL, is conducting vaccine studies to test three different vaccine strategies in an effort to find out which is most effective in preventing a future Ebola outbreak. The study is targeted at survivors who experience health problems, but PREVAIL does not treat the survivors.
JSI, through Advancing Partners & Communities (APC), and the Government of Liberia are providing necessary treatment for Ebola survivors with health problems. APC through the Ebola Transmission and Survivor Services (ETP&SS) program operates under the umbrella of activities managed by USAID’s Global Health Ebola Team in Washington, DC. ETP&SS has made healthcare assistance available to survivors through partnerships with some medical facilities in Liberia, with more agreements underway.
The program works with ministries of health and nongovernmental organizations in the three West African countries most affected by the recent Ebola outbreak: Guinea, Liberia and Sierra Leone. The three core objectives of the program include: strengthening coordination and management of activities for Ebola survivors; improving access for Ebola survivors to health services through health facilities that care for survivors while also combating stigma and discrimination by providers; and building health system capacity to provide specialized health services to care for conditions common to Ebola survivors.
Learn more about the PREVAIL study in the Daily Observer article entitled Liberia: Prevail History Study Impacts Communities>>